DDInter1146 DDInter1180
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease. In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050. In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Memantine {u} (Compound) treats {v} (Disease) Alzheimer's disease
Memantine {u} (Compound) binds {v} (Gene) GRIN3A
Memantine {u} (Compound) upregulates {v} (Gene) TIPARP
Memantine {u} (Compound) palliates {v} (Disease) Parkinson's disease
Memantine {u} (Compound) is included by {v} (Pharmacologic Class) NMDA Receptor Antagonists
Memantine {u} (Compound) downregulates {v} (Gene) GDF15
Memantine {u} (Compound) causes {v} (Side Effect) Leukopenia
Memantine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metformin
Memantine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tromethamine
Memantine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Memantine (Compound) treats Alzheimer's disease (Disease)
Memantine (Compound) binds GRIN3A (Gene)
Memantine (Compound) upregulates TIPARP (Gene)
Memantine (Compound) palliates Parkinson's disease (Disease)
Memantine (Compound) is included by NMDA Receptor Antagonists (Pharmacologic Class)
Memantine (Compound) downregulates GDF15 (Gene)
Memantine (Compound) causes Leukopenia (Side Effect)
Memantine may cause a minor interaction that can limit clinical effects when taken with Metformin
Memantine may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Memantine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin